Zoryve’s regulatory and commercial success, together with pipeline progress, supports Arcutis Biotherapeutics’ positive Q2 ...

Q2 2025 Management View CEO Joseph K. Belanoff highlighted the upcoming approval milestones, stating the company has “2 new drug applications, NDAs in progress in hypercortisolism and ...

AI offers promise in the realm of chronic disease management, including diabetes, obesity, and PCOS, but must be approached with caution.

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.

Q2 2025 Earnings Call Transcript July 31, 2025 Operator: Good afternoon, and welcome to TransMedics Second Quarter 2025 ...

Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

Key Points Non-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. GAAP revenue reached $687.5 million for Q2 2025, beating expectations by $33.6 million and ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures ...